Seeking CRAs who are looking to have influence and impact when it matters most. CRA II/ SCRA (UK): hubs.ly/Q04C72Vq0 CRA (Germany): hubs.ly/Q04C72TD0

Turns out, the cells don’t always have to be alive. Sometimes challenging an assumption starts with asking whether you still need it: hubs.ly/Q04B_Lj00

We are thrilled to announce the arrival of Dr. Amy Lavelle, Vice President, Scientific Solutions at Precision for Medicine! Amy brings with her more than 18 years of bioanalytical and laboratory leadership experience within regulated CRO environments.

Join us at OCT New England to explore how we accelerate drug development through precision medicine. Our expertise spans assay development, translational science & global sample logistics, supported by a worldwide infrastructure to help sponsors navigate complex clinical programs

In our latest Expert Insights article, we explore what happens when emerging clinical trial technologies meet the realities of implementation, and why successful adoption requires more than selecting the right platform. hubs.ly/Q04BCZj30

Visit Precision for Medicine at Booth 1019 at #ESMO2026 and add a ribbon to our Ribbon Wall in honour of the patients, families, caregivers and colleagues whose lives have been touched by cancer.

Want to make a difference? So do we. Senior Director Scientific Affairs - hubs.ly/Q04BnwPg0

Read how scientific rigor, regulatory strategy, and operational execution can come together to help innovative biotech companies move with confidence: hubs.ly/Q04BfFqG0

Deborah Phippard, PhD, Chief Scientific Officer, discusses how autoimmune CAR T trials may advance understanding of immune reset, durability, toxicity management, biomarker strategy, and scalable delivery models. hubs.ly/Q04B61f10

During Breast Cancer Awareness Month, it's worth reflecting on the work that happens behind every advancement in breast cancer research. New therapies require identifying eligible patients, activating the right sites & keeping complex studies moving. hubs.ly/Q04z_y8n0

Discover how Precision got, and kept, this early-phase radiopharmaceutical trial on track: hubs.ly/Q04zr1p70

In this session, Maham will explore the regulatory, operational, & strategic considerations that can make or break combined drug-diagnostic studies while sharing approaches to accelerate development timelines & improve trial execution within Europe's evolving regulatory landscape

Advancing precision in oncology. Precision brings integrated expertise across clinical development and commercialisation to help move complex oncology programs forward. Meet our team at ESMO, Booth 1019.

Don't miss Nithiya Ananthakrishnan's presentation at #CTSS2026 on how emerging biotech companies can meet ICH E6(R3) expectations without building large-scale teams.

Impact outcomes no matter where you work (remotely). Senior Clinical Data Engineer (LATAM): hubs.ly/Q04z0G7s0 Senior Clinical Research Associate (Argentina): hubs.ly/Q04z0FZ-0

Join Precision to discuss how integrated biomarker strategy, scientific expertise and global infrastructure can support complex therapeutic development, including the practical work behind assay development and global sample logistics.

Join us to examine what regenerative medicine companies are saying about the future of the field and the trends most likely to shape development strategies in the years ahead. Get real-world insights from industry leaders working on the next generation of cell and gene therapies.

Program Director Tai Bibbs details the Phase 2 clinical trial and discusses delivery of an investigational drug directly to liver metastases in advanced colorectal cancer. Before the study was finished, the Sponsor awarded us a second trial. Here’s why. hubs.ly/Q04yTjsK0

We're proud to sponsor #CTSS2026 and are looking forward to connecting with biopharma innovators and contributing to the conversations shaping the future of drug development. Book a meeting with Nithiya Ananthakrishnan, Amanda Knapp and Nesia Moradian. hubs.ly/Q04yzzfQ0

Discover how Ireland built a nationally connected early-phase ecosystem and why more sponsors are considering it as part of their European strategy. hubs.ly/Q04yz32z0